RedHill Biopharma Develops SK2 Inhibitor Opaganib as Potential Ebola Treatment

RedHill Biopharma is currently developing its oral drug, opaganib, as a potential treatment for Ebola virus disease, utilizing a dual-action mechanism that targets both the host cells and the virus itself. The company aims to position the drug as a biodefense platform to address the ongoing challenges posed by Ebola outbreaks.

The drug functions as a sphingosine kinase-2 (SK2) inhibitor, a process that restricts the virus’s ability to replicate within human cells while simultaneously modulating the host’s inflammatory response. By targeting host pathways rather than relying solely on viral proteins, the company intends to reduce the likelihood of the virus developing resistance. RedHill Biopharma is now advancing these research efforts to evaluate the drug’s efficacy and safety profile specifically for Ebola, building on previous clinical data regarding the compound’s use in other viral indications. These development activities align with broader biodefense initiatives focused on creating versatile medical countermeasures against emerging infectious threats.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI